EUVIMEDOpdag EUVIMED
Crossref

Sensitization of Multidrug Resistant Cancer Cells to Doxorubicin Using Ebselen by Disturbing Cellular Redox Status

Sugumar Baskar iD, Pradhapsingh Bharathiraja iD, N Rajendra Prasad

Cell Biochemistry and Function · 2024-10 · 42 (7)

DOI: 10.1002/cbf.4134 ↗

At a glance

Journal article in Cell Biochemistry and Function, published online on 2024-10-08. Written by Sugumar Baskar and 2 co-authors. Institution: Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamilnadu, India. Major MEDLINE topics: Organoselenium Compounds, Isoindoles, Doxorubicin, Azoles. Cited 5 times so far (Crossref); 46 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Multidrug resistance (MDR) poses a significant problem in cancer treatment, often causing adverse effects during chemotherapy. Ebselen (Ebs), a synthetic organoselenium compound, affects cellular redox status in cancer cells. In the study, we observed that Ebs disrupted cellular redox balance and sensitized drug‐resistant cells to doxorubicin (DOX) treatment. The combination of Ebs and DOX led to increased intracellular reactive oxygen species (ROS) levels and lipid peroxidation while decreasing the activity of thioredoxin reductase (TrxR) and cellular antioxidants in drug‐resistant cells. Furthermore, this combination treatment demonstrated notable chemosensitizing effects by reducing cell viability and proliferation in MDR cells compared to DOX treatment alone. Additionally, the combination of Ebs and DOX induced DNA fragmentation and exhibited G2/M phase cell cycle arrest. Immunofluorescent analysis revealed that the Ebs and DOX combination upregulated the expression of p53 and p21, which activated the mitochondrial‐dependent apoptotic pathway. The combination treatment also enhanced the upregulation of proapoptotic markers such as Bax, Caspase‐3, ‐9, and cytochrome C, while downregulating the expression of the antiapoptotic marker Bcl‐2. Therefore, the current discoveries suggest that Ebs could be employed as a drug candidate for reversing MDR in cancer cells by regulating cellular redox homeostasis.

Subjects

MeSH terms (MEDLINE)

Organoselenium CompoundsIsoindolesDoxorubicinAzolesDrug Resistance, NeoplasmOxidation-ReductionDrug Resistance, MultipleHumansReactive Oxygen SpeciesCell SurvivalApoptosisCell ProliferationCell Line, Tumor

Author keywords

antioxidantsapoptosischemosensitizationmultidrug resistanceredox status

Substances

Organoselenium CompoundsIsoindolesDoxorubicinebselenAzolesReactive Oxygen Species

Authors and institutions

  • Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar, Tamilnadu, India.

ORCID profiles: Sugumar Baskar, Pradhapsingh Bharathiraja

Cite

APA

Baskar, S., Bharathiraja, P., & Rajendra Prasad, N. (2024). Sensitization of Multidrug Resistant Cancer Cells to Doxorubicin Using Ebselen by Disturbing Cellular Redox Status. Cell Biochemistry and Function, 42(7). https://doi.org/10.1002/cbf.4134

Vancouver

Baskar S, Bharathiraja P, Rajendra Prasad N. Sensitization of Multidrug Resistant Cancer Cells to Doxorubicin Using Ebselen by Disturbing Cellular Redox Status. Cell Biochemistry and Function. 2024;42(7). doi:10.1002/cbf.4134

BibTeX
@article{Baskar2024,
  author = {Baskar, Sugumar and Bharathiraja, Pradhapsingh and Rajendra Prasad, N},
  title = {Sensitization of Multidrug Resistant Cancer Cells to Doxorubicin Using Ebselen by Disturbing Cellular Redox Status},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  volume = {42},
  number = {7},
  doi = {10.1002/cbf.4134}
}
Start for free →